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Abstract
Kappa-opioid (KOP) receptor agonists exhibit analgesic effects without activating reward
pathways. In the search for non-addictive opioid therapeutics and novel chemical tools to study
physiological functions regulated by the KOP receptor, we screened in silico its recently released
inactive crystal structure. A selective novel KOP receptor agonist emerged as a notable result, and
is proposed as a new chemotype for the study of the KOP receptor in the etiology of drug
addiction, depression, and/or pain.
INTRODUCTION
Opioids remain the most widely prescribed and abused class of medicines.1, 2 Addiction is
not the only limiting factor for the effective use of these compounds as powerful painkillers,
antitussives, antidepressants, or antipruritic agents. In addition to social and legal issues
associated with their use for non-medical, recreational purposes, several adverse effects
(e.g., dysphoria, constipation, respiratory depression, nausea, vomiting, etc.)3 hinder their
clinical usefulness and justify the enormous effort put forth by numerous investigators over
the years to discover safer opioid therapeutics and/or non-addictive medications.
Notwithstanding the continued development of many compounds with opioid activity,
ranging from useful agents in the clinic to important chemical tools to study the endogenous
opioid system, a safe, non-addictive and effective opioid drug is yet to be discovered.3
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SUPPORTING INFORMATION
The general procedures for the synthesis of MCKK-17S and MCKK-17R are provided. Table S1 provides a list of the twenty-two
tested compounds. Table S2 reports details of the 500 top-scoring docked compounds from virtual screening at the KOP receptor.
Figure S1 shows the plot of competitive inhibition of 3H-diprenorphine binding at the KOP receptor. Figure S2 shows the synthetic
scheme used to obtain MCKK-17R and MCKK-17S stereoisomers. Figure S3 shows the cAMP accumulation inhibition curves at
DOP and MOP receptors. This information is available free of charge via the Internet at http://pubs.acs.org.
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Notable members of the superfamily of G protein-coupled receptors (GPCRs), mu-, delta-,
and kappa-opioid (or MOP, DOP, and KOP) receptor subtypes4–7 are natural targets for the
majority of opioid ligands. The most clinically used opioid drugs act as agonists at the MOP
receptor,3 and exert addiction liability through activity at this receptor.8, 9 Thus, it has been
proposed that high-affinity selective ligands of the DOP and KOP receptors would provide
more effective routes to discovering non-addictive analgesics.10, 11 In particular, KOP
receptor agonists have been shown to be unable to activate the reward pathway12 while still
acting as effective pain suppressors on the central nervous system (CNS) and/or the
periphery,11 most likely through the Gi/o protein-mediated inhibition of cAMP production,13
the blockade of calcium channels,14 and/or the activation of the inward rectifier potassium
channels.15 Unfortunately, the KOP receptor agonists developed to date are not ideal drugs
as they exert side effects such as dysphoria.16 However, KOP receptor-mediated dysphoric
effects have recently been attributed to the activation of the p38 MAPK pathway following
arrestin recruitment to the activated KOP receptor.16–18 Therefore, KOP receptor-selective
G-protein biased agonists, which do not recruit arrestin, have been proposed to be more
effective analgesics, without the adverse effects triggered by the arrestin pathway.18 We
have recently reported on such a functionally selective G protein-biased KOP receptor
ligand:19 6’-guanidinonaltrindole (6’-GNTI). Although this morphine-derivative ligand is a
promising lead compound for non-addictive analgesics acting at the KOP receptor with
reduced liability for dysphoria, its effective use as a drug is severely limited by its
physicochemical properties and its inability to cross the blood brain barrier.
The lack of a detailed molecular-level understanding of the interactions between opioids and
their receptors has hindered successful receptor-based drug design. By revealing how opioid
ligands bind to their receptors, recent high-resolution crystal structures of all 4 opioid
receptor subtypes, i.e., the MOP,20 DOP,21 KOP,22 and nociceptin/orphanin FQ23 receptors,
offer an unprecedented opportunity to discover novel chemotypes targeting these proteins
that might eventually be developed into more efficacious therapeutics.24, 25
In the search for these non-addictive therapeutics targeting opioid-receptors, we screened in
silico over 4.5 million commercially available, ‘lead-like’ small molecules accessible in
ready-to-dock three-dimensional format in the ZINC database,26 based on complementarity
with the crystallographic binding mode of JDTic into the KOP receptor crystal structure.22
To the best of our knowledge, this is the first virtual screening study at the KOP receptor
using its recently released crystal structure.22 The study led to the identification of 4 novel
small-molecule chemotypes, out of twenty-two tested molecules, acting at the KOP receptor.
The S-stereoisomer of one of these compounds was further characterized as a novel selective
KOP receptor ligand with agonistic activity at this receptor, and as such it represents a
promising candidate for structure-based drug design.
METHODS
Small-molecule Subset, Docking, Selection, and Novelty
We used the ‘lead-like’ subset version of the ZINC database26 that was accessible online on
February, 2nd, 2012 when the molecular docking study was performed. This subset version
contained ~4.5 million commercially available small-molecules selected using the filtering
criteria specified on the ZINC database website. Molecular docking at chain A of the
recently released inactive KOP receptor structure (PDB ID: 4DJH22), following removal of
all non-protein atoms, was performed with DOCK3.6.27–30 The atom positions of the JDTic
crystallographic ligand within the KOP receptor binding pocket were replaced by forty-five
spheres that had been labeled for chemical matching based on the local protein environment.
Default parameters, i.e., a bin size of 0.2 Å, a bin size overlap of 0.1 Å, and a distance
tolerance of 1.2 Å for both the binding site matching spheres and each docked small-
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molecule from the ‘lead-like’ subset, were used for ligand conformational sampling. Partial
charges from the united atom AMBER force field31 were used for all receptor residues with
the exception of Asp138 in transmembrane helix 3. The dipole moment of this residue was
increased by 0.4 per polar atom to favor identification of small molecules that would form
ionic interactions with this residue.32 The KOP receptor was kept rigid while each small
molecule was docked into the binding pocket in an average of 3,073 orientations relative to
the receptor, and an average of 2,132 conformations for each orientation. A score
corresponding to the sum of the receptor-ligand electrostatic and van der Waals interaction
energies, corrected for ligand desolvation, was assigned to each docked molecule and
configuration within the KOP receptor binding pocket. The specific energy estimates were
obtained as we recently described for an analogous study.33 The best scoring conformation
of each docked molecule was further subjected to 100 steps of energy minimization with the
protein residues kept rigid. Twenty-two compounds, termed here MCKK-1–22, and listed in
Table S1, were selected from visual inspection of the 500 top-scoring docked compounds
(Table S2) based on criteria discussed in Results and Discussion. Similarity between these
molecules and the 9,934 opioid receptor ligands that are annotated in the ChEMBL database
[https://www.ebi.ac.uk/chembl/] (Table S1) was quantified using an in-house script in R
language that calculates Tanimoto coefficients (Tc) to the nearest neighbors based on
extended connectivity fingerprint maximum distances 4 (ECFP4) and the protocol we
recently reported.33 Tc values range from 0 to 1, with the 0 value indicating maximally
dissimilar compounds and 1 indicating maximally similar ones.34 As suggested in the
literature,35 molecules are considered reasonably similar if their Tc value is above 0.40.
Molecules for testing were purchased from commercial vendors. Specifically, compounds
MCKK-1, MCKK-4, MCKK-8, MCKK-15, MCKK-18 and MCKK-21–22 were obtained
from ChemBridge, MCKK-2 from the National Cancer Institute of the National Institutes of
Health, MCKK-3 from Labotest, MCKK-5–7, MCKK-9–13, MCKK-16–17 and MCKK-19
from Enamine, MCKK-14 from Florida Heterocyclic Compounds, and MCKK-20 from
Molecular Diversity Preservation International.
Constructs for Expression Vectors and Transfection
The cDNAs for human KOP (hKOP) receptor and the G protein GαoB were obtained from
the Missouri S&T cDNA Resource Center. For arrestin recruitment experiments, full-length
Renilla luciferase 8 (RLuc8, provided by S. Gambhir) was fused in-frame to the C terminus
of the hKOP receptor in the pcDNA3.1 vector. The following human G protein constructs
were provided by C. Gales:36, 37 GαoB with RLuc8 inserted at position 91 (GαoB-RLuc8);
untagged Gβ1 (β1); untagged Gγ2 (γ2). The human γ2 subunit was fused to full-length
mVenus at its N terminus (mVenus-γ2), and we used the fusion construct human arrestin3-
mVenus previously described.38 All constructs were confirmed by sequencing analysis. A
total of 20 µg of plasmid cDNA (e.g. 0.2 µg of hKOR-RLuc8, 15 µg of arrestin3-mVenus,
and 4.8 µg of pcDNA3.1) was transfected into HEK-293T cells using polyethylenimine
(Polysciences Inc.) in a 1:3 ratio in 10-cm dishes. Cells were maintained in culture with
DMEM supplemented with 10% FBS. The transfected ratio among receptor, Gα, β1, and γ2,
or arrestin was optimized by testing various ratios of plasmids encoding the different
sensors. Experiments were performed 48 h after transfection.
Membrane Preparations and Binding Assays
Two days after transfection with human KOP receptor and GαoB, HEK293T cells were
lysed and membranes were prepared in HEPES buffer (NaCl 140 mM, KCl 5.4 mM, HEPES
25 mM, EDTA 1 mM, MgCl2 2 mM, BSA 0.006%, pH 7.4) using a Polytron homogenizer.
Membranes were incubated with 3H-diprenorphine (0.3 nM) (PerkinElmer) at room
temperature for 1 h in a final volume of 1 ml, in the absence or presence of various
concentrations of each small-molecule selected from the virtual screening. Membranes were
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then harvested using a Brandel cell harvester through a Whatman FPD-24 934AH glass-
fiber filter and washed three times with ice-cold wash Buffer (Tris-HCl 10 mM, NaCl 120
mM, pH 7.4). Non-specific binding was determined using 400 nM of NorBNI.
BRET-based G protein activation, arrestin recruitment and cAMP accumulation assays
BRET was performed as described.39 Briefly, two days after transfection, cells were
harvested, washed, and re-suspended in a phosphate-buffered saline (PBS) solution.
Approximately 200,000 cells/well were distributed in 96-well plates, and 5 µM
coelenterazine H (luciferase substrate) was added to each well. Five minutes after the
addition of coelenterazine H, ligands were added to each well. After 2 min for G protein
activation or 5 min for arrestin recruitment, the BRET signal was determined by quantifying
and calculating the ratio of the light emitted by mVenus, the energy acceptor (510–540 nm),
over that emitted by RLuc8, the energy donor (485 nm). The drug-induced BRET signal was
normalized, taking the Emax of the ethylketocyclazocine (EKC)-induced response as 100%.
To measure cAMP accumulation, we used a BRET-based cAMP in a previously described
YFP-Epac-RLuc (CAMYEL) assay.40 GαoB, β1, and γ2 were co-expressed to enhance the
signal-to-noise ratio, and the cells were treated for 5 min with 100 µM forskolin prior to
stimulation.40 The data were normalized and represented as the percentage of forskolin-
stimulated cAMP accumulation with 0 defined as the maximal inhibition elicited by EKC.
Chemical Synthesis of MCKK-17 Stereoisomers
All reagents purchased from chemical suppliers were used without further purification and
reactions monitored using Thin-layer chromatography (TLC) on 0.25 mm Analtech GHLF
silica gel plates using EtOAc/n-hexanes and visualized at 254 nm. Column chromatography
was performed on silica gel (40 – 63 µm particle size, 230–400 mesh) from Sorbent
Technologies (Atlanta, GA). NMR spectra were recorded on either a Bruker DRX-400 with
a H/C/P/F QNP gradient probe or a Bruker Avance AV-III 500 with a dual carbon/proton
cryoprobe using δ values in ppm as standardized from tetramethylsilane (TMS) and J (Hz)
assignments for 1H resonance coupling and 13C fluorine coupling. High resolution mass
spectrometry data were collected on a LCT Premier (Waters Corp.) time-of-flight mass
spectrometer. Analytical HPLC was performed on an Agilent 1100 Series Capillary HPLC
system with diode array detection at 254.8 nm on a CRIRALCEL OD-H column (4.6 × 150
mm), Daicel Chemical Industries, Ltd. using isocratic elution in 97% hexanes and 3% 2-
Propanol at a flowrate of 1.25 mL/min. General procedures for the synthesis of tertbutyl 2-
(thiazol-2-ylcarbamoyl)pyrrolidine-1-carboxylate (2S and 2R), as well as 1-(2-(3-
fluorophenylamino)-2-oxoethyl)-N-(thiazol-2-yl)pyrrolidine-2-carboxamide (MCKK-17S
and MCKK-17R) are provided in Supporting Information.
RESULTS AND DISCUSSION
Structure-Based Identification of Novel Chemotypes Targeting the KOP Receptor
We screened in silico 4,554,059 commercially-available, “lead-like” compounds from the
ZINC database26 based on complementarity with the crystallographic binding mode of
JDTic into the KOP receptor binding pocket. The 500 top-scoring docking hits (Table S2;
0.01% of the docked library) were visually inspected and prioritized based on features that
an automatic molecular docking screen does not take into account. Specifically, molecules
were selected based on the following criteria: a) chemotype diversity; b) the presence of
polar interactions between the ligand and the Asp138 residue; c) interactions with KOP
receptor residues in the binding pocket that are different in DOP and MOP receptors, d)
limited flexibility, e) different binding modes from classical alkaloids as revealed by DOP21
and MOP20 receptor crystal structures, and f) purchasability, i.e., molecules were readily
available for purchase. Based on these criteria, twenty-two small molecules were purchased
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from the set of 500 highest-scored compounds. These molecules, labeled MCKK-1–22 in
Table S1, corresponded to the DOCK scoring ranks 1, 80, 87, 97, 111, 127, 137, 210, 253,
269, 276, 346, 347, 360, 379, 402, 403, 404, 411, 427, 452, and 472, respectively. As shown
in Table S1, these compounds were found to be significantly different from annotated opioid
receptor ligands in the ChEMBL database, as indicated by small ECFP4-based Tc values.35
These data confirm the chemotype novelty of all selected agents.
One of the Top-Scoring Docked Molecules is a Selective Agonist at the KOP Receptor
The primary experimental testing of MCKK-1–22 consisted of performing a competitive
inhibition binding assay at the hKOP receptor. Membranes of HEK293T cells transfected
with the hKOP receptor and GαoB were prepared and incubated with 3H-diprenorphine (0.3
nM) in the absence or presence of 10 or 100 µM of each small-molecule from the virtual
screening. Four molecules, MCKK-4, MCKK-5, MCKK-13 and MCKK-17 partially but
significantly inhibited 3H-diprenorphine binding (Figure S1) at 100 µM and their properties
were therefore further investigated.
To assess whether any of these molecules had agonistic activity, we used a BRET-based G
protein activation assay where the hKOP receptor was co-expressed in HEK293T cells with
GαoB-RLuc8, β1, and mVenus-γ2, as discussed in Methods. The drug-induced BRET signal
is interpreted as a dissociation of and/or conformational change within the Gαβγ complex,
and thus, as the activation of the co-expressed G protein. Among the selected molecules,
only the racemic mixture MCKK-17R/S activated GαoB with a potency of 8.3 ± 4.0 µM
(Figure 1A). Thus, we proceeded to the chemical synthesis of the R and S stereoisomers of
MCKK-17 using commercially available N-(tert-butoxycarbonyl)-L-proline (1R) or N-(tert-
butoxycarbonyl)-D-proline (1S) (Figure S2) to identify the active molecule. The appropriate
proline was coupled to 2-aminothiazole using 1,1’-carbonyldiimidazole (CDI) in CH2Cl2
under anhydrous conditions41, 42 to afford the corresponding Boc-protected thiazoles (2R
and 2S). Removal of the Boc group under acidic conditions followed by alkylation with 2-
chloro-N-(3-fluorophenyl)acetamide43, 44 under basic conditions in DMF overnight at 80 °C
gave stereoisomers MCKK-17S and MCKK-17R. The purity of MCKK-17S and
MCKK-17R was determined to be at least 99% by integration of the UV trace from chiral
HPLC (data not shown). MCKK-17S resulted in the most active stereoisomer at the hKOP
receptor. Indeed, MCKK-17S displayed full agonism relative to EKC at the hKOP receptor
with an EC50 of 7.2 ± 3.8 µM, whereas MCKK-17R displayed a potency of only 120 ± 9
µM. None of the other molecules, MCKK-4, MCKK-5 and MCKK-13, significantly
activated GoB (Figure 1A), suggesting that, in contrast to MCKK-17R/S, those molecules
are antagonists at the hKOP receptor.
To assess the degree of selectivity of MCKK-4, MCKK-5, MCKK-13, MCKK-17R or
MCKK-17S for the hKOP over the DOP and MOP receptors, we performed competitive
inhibition of 3H-diprenorphine (0.3 nM) binding in the absence or presence of various
concentrations of each molecule, and determined their Ki values for each receptor (Table 1).
EKC was used as a reference at all three receptors with recorded Ki values of 20 ± 6 nM at
hKOP receptor, 250 ± 31 nM at the DOP receptor, and 170 ± 100 nM at the MOP receptor.
Consistent with the first experimental testing (Figure S1), the aforementioned five molecules
displayed a relatively weak affinity (Ki values) at the hKOP receptor, between 100 and 500
µM (Table 1). Among them, only MCKK-17S exhibited selectivity for the hKOP receptor
with a measured affinity of 120 ± 38 µM at this receptor, and no detectable affinity at DOP
and MOP receptors (>1000 µM).
To further assess the selectivity of MCKK-17S for the hKOP receptor (Table 1), we also
investigated whether the racemic mixture MCKK-17R/S, as well as the two stereoisomers,
displayed agonistic activity at the DOP and MOP receptors (Figure 1B). Neither the racemic
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nor the MCKK-17 stereoisomers displayed significant activity at the MOP receptor, and
they only weakly activated the DOP receptor (> 1000 µM). Notably, MCKK-17R, the less
active steroisomer at the hKOP receptor, was the most active enantiomer at the DOP
receptor. In contrast, MCKK-17S did not significantly activate the DOP receptor,
confirming its selectivity at the hKOP receptor. These results were confirmed using a
BRET-based cAMP accumulation inhibition assay (Figure 1C) to monitor the agonistic
activity of the selected molecules at the hKOP receptor (Figure 1C), as well as at the DOP
and MOP receptors (Figure S3).
Finally, we investigated whether MCKK-17 and the corresponding stereoisomers could
recruit arrestin. MCKK-17R/S and MCKK-17S recruited arrestin3, with potencies of 160 ±
38 µM and 120 ± 47 µM, respectively, whereas MCKK-17R only weakly recruited arrestin3
at the highest concentration (potency > 1000 µM) (Figure 1D), consistent with its weaker
potency at the hKOP receptor for G protein activation.
CONCLUSIONS
Although several non-peptidic selective molecules targeting the KOP receptor have been
developed, we are still far from a therapeutically effective KOP receptor drug. Our structure-
based virtual screening and compound selection criteria yielded the discovery of a novel
small-molecule chemotype that acts as a selective, full agonist at the KOP receptor. To the
best of our knowledge, this is the first time that a virtual screening based on an antagonist-
bound GPCR crystal structure has identified an agonist. We were pleased to note that the
chemical scaffold of the identified hit refers to a selective KOP receptor compound that has
very little similarity with all opioid receptor agonists or antagonists annotated in ChEMBL,
and that it has never been reported to be an opioid receptor ligand. In summary, MCKK-17S
is a promising new lead compound for structure-based ligand optimization aimed at
discovering potent non-addictive analgesics. Although the parent compound MCKK-17S is
not biased toward G protein activation over arrestin, the chemical scaffold is well suited to
structure-guided modifications, raising the prospects of maintaining selectivity while
increasing potency and building G protein bias.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. MCKK-17-S is a selective hKOP receptor agonist
A and B, the hKOP receptor (A), DOP or MOP receptors (B) were co-expressed with GαoB-
RLuc8, β1, and mVenus-γ2 to assay G protein activation. A, Only MCKK-17-R/S exhibited
agonistic activity at the hKOP receptor and MCKK-17S was the more active stereoisomer.
B, MCKK-17S is selective for hKOP relative to MOP and DOP receptors. C, The hKOP
receptor was co-expressed with a BRET-based CAMYEL sensor to assay inhibition of
forskolin-stimulated cAMP accumulation. D, The hKOP receptor, fused to RLuc8, was co-
expressed with arrestin3 (Arr3) fused to mVenus to assay arrestin recruitment to the
activated receptor. Error bars in A, B, C and D indicate S.E.
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Table 1
Active compounds and their corresponding chemical structure, DOCK scoring rank from the virtual screening







MCKK-4 (97) 290 ± 210 640 ± 190 910 ± 840
MCKK-5 (111) 130 ± 81 180 ± 190 430 ± 140
MCKK-13 (347) 450 ± 27 300 ± 99 >10000
MCKK-17 (403) 17R: 2900 ± 960 17R: 290 ± 320 17R: 510 ± 640
17S: 120 ± 38 17S: >10000 17S: >10000
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